Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Appili Therapeutics Announces that FDA Accepts The ATI-1501 NDA
Details : ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible org...
Product Name : ATI-1501
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible org...
Product Name : ATI-1501
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Poria Cocos Mushroom Extract,Aloe vera,Rosemary Extract
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UP360 is a naturally-derived extracts from both the Poria cocos mushroom and rosemary as well as Aloe vera gel powder. The UP360 produces antioxidant, anti-inflammatory, and immunomodulatory effects.
Product Name : UP360
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2023
Lead Product(s) : Poria Cocos Mushroom Extract,Aloe vera,Rosemary Extract
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible org...
Product Name : ATI-1501
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 13, 2023
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Saptalis Pharm
Deal Size : Undisclosed
Deal Type : Agreement
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Details : Under the terms of the amended agreement, Saptalis will assume responsibility for development and commercialization of ATI-1501 in Europe and Latin America (collectively, the “Expanded Territories”).
Product Name : ATI-1501
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 02, 2022
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Saptalis Pharm
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Acacia Catechu,Scutellaria Baicalensis
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UP446, a natural health ingredient developed by Unigen, contains Acacia catechu and Scutellaria baicalensis, botanicals with antioxidant and anti-inflammatory properties; however, this is the first study to examine these ingredients using a human vaccine...
Product Name : UP446
Product Type : Vaccine
Upfront Cash : Inapplicable
June 12, 2022
Lead Product(s) : Acacia Catechu,Scutellaria Baicalensis
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2307
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Long Zone Holdings Inc.
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Appili shall grant LZH an exclusive license to commercialize Appili’s future approved products in Latin America, Canada, and Israel (collectively, the “Territory”), excluding ATI-1501 in Latin America, which was recently licensed to existing partne...
Product Name : ATI-2307
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 29, 2022
Lead Product(s) : ATI-2307
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Long Zone Holdings Inc.
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ATI-2307
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : The Lind Partners
Deal Size : $4.0 million
Deal Type : Financing
Appili Therapeutics Announces Update to Funding Agreement With The Lind Partners
Details : Appili Therapeutics will use the proceed from Lind, to expand and advance it's diversified anti-infective pipeline of four potential products through key development milestones in 2022, including a Phase 2 start for novel antifungal ATI-2307.
Product Name : ATI-2307
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 22, 2021
Lead Product(s) : ATI-2307
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : The Lind Partners
Deal Size : $4.0 million
Deal Type : Financing
Lead Product(s) : bacTRL-Spike Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Research Council Industrial Research Assistance Program
Deal Size : $2.8 million
Deal Type : Funding
Symvivo Corporation Receives Funding for COVID-19 Vaccine Program
Details : The funding follows a notification Symvivo received from the Government of Canada indicating it had reviewed Symvivo’s proposal and its bacTRL-Spike™ vaccine candidate had met the required scientific and technical thresholds for funding.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : bacTRL-Spike Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Research Council Industrial Research Assistance Program
Deal Size : $2.8 million
Deal Type : Funding
Lead Product(s) : OB-002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 study design included open-label single-dose (vaginal and rectal) and multi-dose product (vaginal) administration of OB-002H gel to study participants followed by a randomised, double-blind, placebo-controlled multi-dose (vaginal) phase of pr...
Product Name : OB-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2020
Lead Product(s) : OB-002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable